October 31, 2016
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Attention: Suzanne Hayes, Assistant Director, Office of Healthcare and Insurance
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Re: |
Xenetic Biosciences, Inc. Registration Statement on Form S-1 (File No. 333-211249) |
Acceleration Request Requested Date: November 1, 2016 Requested Time: 4:00 p.m., Eastern Daylight Time |
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-211249) (the “Registration Statement”) of Xenetic Biosciences, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Eastern Daylight Time, on November 1, 2016, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Taft Stettinius & Hollister LLP, by calling Mitchell D. Goldsmith at (312) 836-4006.
Thank you for your assistance in this matter.
Very truly yours, | ||
Xenetic Biosciences, Inc. | ||
By: | /s/ M. Scott Maguire | |
Michael Scott Maguire | ||
Chief Executive Officer |
cc: | David Strupp | Ladenburg Thalmann & Co. Inc. |
Michael Maline | Goodwin Procter LLP | |
Mitchell D. Goldsmith | Taft Stettinius & Hollister | |
Jeremy Stonehill | Taft Stettinius & Hollister |